Boehringer Ingelheim said it will end research into developing a porcine circovirus type 2 ready-to-use vaccine combination to focus its attention on its PCV2 Mycoplasma hyopneumoniae vaccine.
Boehringer Ingelheim is still recalling products that were made at its Ben Venue plant in Bedford, OH, even though it no longer owns the massive site.
Boehringer Ingelheim is finding it difficult to get the stink of the troubled Ben Venue Bedford, OH, operations off its shoes. It closed the site last year and sold it last month but is still having to recall products produced there that might be contaminated.
Just as Eli Lilly and Boehringer Ingelheim's new diabetes drug Jardiance hit store shelves in the U.S., cost-effectiveness watchdogs in the U.K. were considering whether to give it their blessing. The verdict as of Thursday morning? Nay.
The FDA's Pulmonary-Allergy Drugs Advisory Committee voted 10-3 to recommend approval of Boehringer Ingelheim's mist formulation of its dry-powder inhalable treatment for chronic obstructive pulmonary disease.
Eli Lilly won't be able to sell its Lantus copycat--dubbed Basaglar--for at least 30 months because of a patent fight with Sanofi.
Eli Lilly has won a "tentative" FDA approval for its knockoff of Sanofi's Lantus, but don't look for it at a pharmacy anytime soon. The insulin glargine injection--to be marketed as Basaglar eventually in the U.S.--faces an automatic 30-month stay after Sanofi filed a suit against Lilly and its partner Boehringer Ingelheim claiming patent infringement.
Boehringer Ingelheim Monday laid out the bad news about its revenues for the year. Sales were down more than 3% in the first 6 months and will be down in single digits for the year. With no relief in sight this year, the German company is looking to cut costs, starting with positions in its home country.
Boehringer Ingelheim is having a tough year with its drug business, seeing more than a 5% fall in sales in the first 6 months. The Germany-based company forecasts revenues will be down for the year as well, but it says by getting its house in order, its finances can improve after that. It has settled some nagging litigation and sold some assets, and it's about ready to launch some newly approved drugs.
Without the safety concerns that plague its competitors, Jardiance may be able to make a splash.